Epithelial Ovarian Cancer
Conditions
Keywords
ovarian cancer, metformin, carboplatin, paclitaxel
Brief summary
Molecularly targeted agents which inhibit the mammalian target of rapamycin (mTOR) pathway and/or circumvent p53 in the induction of apoptosis are exciting potential targets in ovarian cancer. Metformin is a biguanide, widely used in the treatment of type 2 diabetes mellitus, that has shown anti-cancer activity in preclinical studies. The main mechanism of metformin's effect is mTOR pathway inhibition and, in addition, it has been shown to circumvent p53-induced apoptosis making it an exciting, potentially effective drug in ovarian cancer.
Detailed description
A phase Ib, single-centre, dose-escalation trial with a traditional escalation rule with fixed dose levels (3 + 3 rule). The recommended phase II dose will be defined as the maximum predefined dose level at which 0 of 3 or ≤ 1 of 6 subjects experience a drug-related dose limiting toxicity (DLT) during cycle 1 and 2 of treatment. An estimated 10-20 patients will be required for this study.
Interventions
DRUGMetformin
Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
DRUGCarboplatin
Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
DRUGPaclitaxel
Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
Sponsors
University Medical Center Groningen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with advanced stage (FIGO III-IV), histologically confirmed and documented epithelial ovarian carcinoma * Patients eligible for neo-adjuvant carboplatin/paclitaxel chemotherapy prior to surgical debulking OR patients with relapsed or progressive ovarian cancer after initial treatment eligible for palliative carboplatin/paclitaxel chemotherapy * Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0-2 * Age ≥ 18 years * Laboratory Requirements - within 7 days prior to enrolment: * absolute neutrophil count (ANC) ≥1.5 x 109/L * platelets \> 100 x 109/L * hemoglobin \>9g/dl. Patients may be transfused or use erythropoietin to maintain hemoglobin values ≥ 9 g/dl. * hepatic function: bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST)/ALT≤2.5×ULN * estimated creatinine clearance ≥ 60ml/min * Before patient registration/randomization, written informed consent for the trial must be given according to International Conference on Harmonisation (ICH)/ good clinical practice (GCP), and national/local regulations.
Exclusion criteria
* Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study. * Metformin within 4 weeks prior to enrolment. * Symptomatic central nervous system (CNS) metastasis * Pre-existing peripheral neuropathy ≥ Common toxicity criteria (CTC) grade 2. * Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start. * Women of childbearing potential (defined as \<2 years after last menstruation and not surgically sterile) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the study and for 6 months after the last study medication. * Known hypersensitivity to any of the study drugs or excipients. * Serious active infection requiring i.v. antibiotics at enrolment. * Unstable medical conditions. * Evidence of any other medical conditions, physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events as a measure of safety and tolerability | 1-2 years | Data will be used to determine recommended phase 2 dose |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (AUC, Tmax,Cmax) of carboplatin and paclitaxel chemotherapie | 1-2 years |
Countries
Netherlands
Outcome results
None listed